4年以上：使用基础胰岛素与胰高血糖素样肽-1受体激动剂的固定比例组合或基础胰岛素与钠-葡萄糖协同转运蛋白2抑制剂的固定比例组合简化复杂胰岛素治疗方案。 - Suppr

BEYOND 4 years: simplification of complex insulin regimens with a fixed-ratio combination of basal insulin plus a GLP-1 receptor agonist or basal insulin plus an SGLT-2 inhibitor.

作者信息

Giugliano Dario, Longo Miriam, Caruso Paola, Scappaticcio Lorenzo, Pontillo Alessandro, Di Martino Nicole, Porcellini Chiara, Angelino Silvia, Caputo Mariangela, Bellastella Giuseppe, Maiorino Maria Ida, Esposito Katherine

机构信息

Department of Advanced Medical and Surgical Science, University of Campania "Luigi Vanvitelli", Naples, Italy.

Department of Life Sciences, Health and Health Professions, Link Campus University, Rome, Italy.

出版信息

Diabetologia. 2025 Aug 28. doi: 10.1007/s00125-025-06535-y.

DOI:10.1007/s00125-025-06535-y

PMID:40877579

Abstract

摘要

相似文献

BEYOND 4 years: simplification of complex insulin regimens with a fixed-ratio combination of basal insulin plus a GLP-1 receptor agonist or basal insulin plus an SGLT-2 inhibitor.

Diabetologia. 2025 Aug 28. doi: 10.1007/s00125-025-06535-y.

BEYOND 2 years: durability of metabolic benefits by simplification of complex insulin regimens in type 2 diabetes.

Endocrine. 2024 Feb;83(2):399-404. doi: 10.1007/s12020-023-03547-9. Epub 2023 Oct 3.

Feasibility of Simplification From a Basal-Bolus Insulin Regimen to a Fixed-Ratio Formulation of Basal Insulin Plus a GLP-1RA or to Basal Insulin Plus an SGLT2 Inhibitor: BEYOND, a Randomized, Pragmatic Trial.

Diabetes Care. 2021 Jun;44(6):1353-1360. doi: 10.2337/dc20-2623. Epub 2021 Apr 21.

Practical limitations of complex insulin therapies in type 2 diabetes: Focus on therapy simplification using fixed-ratio combinations of basal insulin and a glucagon-like peptide-1 receptor agonist.

Diabetes Obes Metab. 2025 Aug;27 Suppl 7:42-54. doi: 10.1111/dom.16645. Epub 2025 Jul 28.

Impact of real-time glucose monitoring using FreeStyle Libre 3 on glycaemia in type 2 diabetes managed with basal insulin plus SGLT2 inhibitor and/or GLP-1 agonist: the FreeDM2 randomised controlled trial protocol.

BMJ Open. 2025 Apr 15;15(4):e090154. doi: 10.1136/bmjopen-2024-090154.

Insulin and Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Diabetes Care. 2017 Apr;40(4):614-624. doi: 10.2337/dc16-1957.

Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis.

Lancet. 2014 Dec 20;384(9961):2228-34. doi: 10.1016/S0140-6736(14)61335-0. Epub 2014 Sep 11.

An overview of randomized clinical trials of fixed-ratio combinations of basal insulin plus GLP-1RA (injectable therapy): Lessons for advancing therapy in people with type 2 diabetes.

Diabetes Obes Metab. 2025 Aug;27 Suppl 7:14-25. doi: 10.1111/dom.16616. Epub 2025 Jul 17.

Basal insulin plus GLP-1 RA or SGLT2 inhibitor was noninferior to basal-bolus insulin intensification for HbA in T2DM.

Ann Intern Med. 2021 Sep;174(9):JC106. doi: 10.7326/ACPJ202109210-106. Epub 2021 Sep 7.

What is the 'real-world' experience with fixed-ratio combination therapy (insulin + GLP-1 receptor agonist) in routine clinical practice? Take-home messages for clinicians regarding key outcomes.

Diabetes Obes Metab. 2025 Aug;27 Suppl 7:26-41. doi: 10.1111/dom.16593. Epub 2025 Jul 10.

本文引用的文献

Fixed-ratio combination of GLP-1 receptor agonist and basal insulin: simplifying type 2 diabetes treatment.

Endocrine. 2025 Apr 24. doi: 10.1007/s12020-025-04243-6.

BEYOND 2 years: durability of metabolic benefits by simplification of complex insulin regimens in type 2 diabetes.

Endocrine. 2024 Feb;83(2):399-404. doi: 10.1007/s12020-023-03547-9. Epub 2023 Oct 3.

Expert Panel Guidance and Narrative Review of Treatment Simplification of Complex Insulin Regimens to Improve Outcomes in Type 2 Diabetes.

Diabetes Ther. 2022 Apr;13(4):619-634. doi: 10.1007/s13300-022-01222-2. Epub 2022 Mar 11.

Diabetes Care. 2021 Jun;44(6):1353-1360. doi: 10.2337/dc20-2623. Epub 2021 Apr 21.

Insulin and Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Diabetes Care. 2017 Apr;40(4):614-624. doi: 10.2337/dc16-1957.

Achievement of goals in U.S. diabetes care, 1999-2010.

N Engl J Med. 2013 Apr 25;368(17):1613-24. doi: 10.1056/NEJMsa1213829.

Efficacy of insulin analogs in achieving the hemoglobin A1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials.

Diabetes Care. 2011 Feb;34(2):510-7. doi: 10.2337/dc10-1710. Epub 2011 Jan 7.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

BEYOND 4 years: simplification of complex insulin regimens with a fixed-ratio combination of basal insulin plus a GLP-1 receptor agonist or basal insulin plus an SGLT-2 inhibitor.

作者信息

机构信息

Department of Advanced Medical and Surgical Science, University of Campania "Luigi Vanvitelli", Naples, Italy.

Department of Life Sciences, Health and Health Professions, Link Campus University, Rome, Italy.

出版信息

Diabetologia. 2025 Aug 28. doi: 10.1007/s00125-025-06535-y.

DOI:10.1007/s00125-025-06535-y

PMID:40877579

Abstract

摘要

BEYOND 4 years: simplification of complex insulin regimens with a fixed-ratio combination of basal insulin plus a GLP-1 receptor agonist or basal insulin plus an SGLT-2 inhibitor.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

BEYOND 4 years: simplification of complex insulin regimens with a fixed-ratio combination of basal insulin plus a GLP-1 receptor agonist or basal insulin plus an SGLT-2 inhibitor.

作者信息

机构信息

出版信息

相似文献

本文引用的文献